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Abstract
Cancer patients show large individual variation in their response to chemotherapeutic agents. Gemcitabine (dFdC) and
AraC, two cytidine analogues, have shown significant activity against a variety of tumors. We previously used expression
data from a lymphoblastoid cell line-based model system to identify genes that might be important for the two drug
cytotoxicity. In the present study, we used that same model system to perform a genome-wide association (GWA) study to
test the hypothesis that common genetic variation might influence both gene expression and response to the two drugs.
Specifically, genome-wide single nucleotide polymorphisms (SNPs) and mRNA expression data were obtained using the
Illumina 550KH HumanHap550 SNP Chip and Affymetrix U133 Plus 2.0 GeneChip, respectively, for 174 ethnically-defined
‘‘Human Variation Panel’’ lymphoblastoid cell lines. Gemcitabine and AraC cytotoxicity assays were performed to obtain IC50
values for the cell lines. We then performed GWA studies with SNPs, gene expression and IC50 of these two drugs. This
approach identified SNPs that were associated with gemcitabine or AraC IC50 values and with the expression regulation for
29 genes or 30 genes, respectively. One SNP in IQGAP2 (rs3797418) was significantly associated with variation in both the
expression of multiple genes and gemcitabine and AraC IC50. A second SNP in TGM3 (rs6082527) was also significantly
associated with multiple gene expression and gemcitabine IC50. To confirm the association results, we performed siRNA
knock down of selected genes with expression that was associated with rs3797418 and rs6082527 in tumor cell and the
knock down altered gemcitabine or AraC sensitivity, confirming our association study results. These results suggest that the
application of GWA approaches using cell-based model systems, when combined with complementary functional
validation, can provide insights into mechanisms responsible for variation in cytidine analogue response.
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Introduction
The application of high-throughput genomic techniques makes
it possible to identify variation across the genome that may help to
predict clinical response to drug treatment [1–5]. Wide variations
in response to many antineoplastic drugs exist in the clinic.
Therefore, it is crucial to identify biomarkers that will help make it
possible to maximizing efficacy while minimize drug-related
toxicity. One possible explanation for variation in response to
chemotherapy is genetic variation that influences gene expression
and, ultimately, impacts variation in drug response phenotypes
[6–8]. Most previous studies have focused on biomarkers in tumor
tissue and their relationship with therapeutic response [9–15].
While identifying genetic biomarkers in the tumor is important for
understanding tumorigenesis and for predicting prognosis and
treatment response, individual variation in germline DNA can also
play an important role in drug response. Gemcitabine and AraC
are two cytidine analogues that are widely used to treat a variety of
cancers [16–19]. Only 20% of the pancreatic cancer patients
treated with gemcitabine have life expectancy over 1 year. Many
side effects such as GI and hematological side effects are associated
with the use of these drugs. Therefore, it would be important to
identify biomarkers that might help to select responsive patients
and avoid side effects during treatment with these drugs.
In a present study, we took advantage of ethnically diverse
Coriell ‘‘Human Variation Panel’’ lymphoblastoid cell lines to test
the hypothesis that genetic variation across the genome in
germline DNA might impact gemcitabine and AraC cytotoxicity.
These cell lines were obtained from three different ethnic groups:
Caucasian-Americans, African-Americans and Han Chinese-
Americans. Although they are Epstein-Barr virus (EBV) trans-
formed cell lines with expression profiles distinctive from those in
tumor cells, these cell lines provide an opportunity to query the
impact of common genomic variation on drug response [5,20–25].
Specifically, we have now used these cell lines to perform GWA
experiments designed to identify genetic variation that might be
associated with variation in gene expression and then, subse-
quently, with variation in gemcitabine and AraC IC50 values. We
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7765identified 19 and 30 SNPs associated with gemcitabine and AraC
IC50 that were also associated with the expression of 29 and 30
genes, respectively. At the same time, this variation in gene
expression was associated with IC50 values for the two drug. We
then focused on 2 SNPs with unknown function in the intron and
59-flank region (FR) of a gene encoding the IQ motif containing
GTPase activating protein 2 (IQGAP2),(rs3797418) and a gene
encoding transglutaminase 3 (TGM3), (rs6082527), respectively.
IQGAP2 (rs3797418) was significantly associated with IC50 for both
drugs and TGM3 (rs6082527) was significantly associated with the
expression of multiple genes and with gemcitabine IC50 values.
These two SNPs are not in linkage disequilibrium (LD) with each
other. Because gemcitabine is used to treat a variety of solid
tumors including pancreatic cancer, in order to validate this
association obtained using lymphoblastoid cell lines, we selected
two pancreatic tumor cell lines to perform siRNA knock down of
three selected genes (MGMT, VAV3 and GPM6A) with expression
levels that were associated with either or both of the rs3797418
and rs6082527 SNPs. Those results indicated that down-
regulation of VAV3 and GPM6A altered gemcitabine or AraC
response, as predicted by the association studies. In addition, we
also took the advantage of the fact that we had information with
regard to SNPs for all of the genes involved in the cytidine
analogue activation and deactivation pathway, and performed
SNP expression as well as drug cytotoxicity analyses with those
genes. These results suggest that a genome-wide approach can
help to identify genetic variation that might be important for
variation in drug response through the trans-regulation of the
expression of multiple genes.
Results
Genome-Wide SNP vs. Gemcitabine IC50 Association
Study
A total of 561,464 SNPs were genotyped on the Illumina 550K
SNP array and were subjected to quality control prior to
performing the association study. As a result, we first removed
the 8,222 SNPs that had call rate ,95% as well as the 33,564
SNPs with Minor Allele Frequencies (MAFs) ,5%. Finally, we
removed 4,639 SNPs that deviated from Hardy-Weinberg
Equilibrium (HWE) using a stringent threshold of p,0.001.
Therefore, a total of 515,039 SNPs were used in a genome-wide
SNP analyses for 171 cell lines. Figure 1 depicts graphically and
Tables S1 and S2 list the 492 SNPs associated with gemcitabine
IC50 and the 553 SNPs associated with AraC IC50 with p-values
,10
23. 58 and 68 SNPs among these 492 and 553 SNPs had p-
values ,10
24, respectively. These 58 and 68 SNPs were in or near
47 or 59 unique genes on the basis of the annotation provided by
Illumina, genome build 36.1. 14 of those 58 SNPs were in 39-
flanking regions, 19 in 59-flanking regions, 23 in intragenic regions
of the closest gene, while only two were in the coding regions for
the PIGB and HLA-DRA genes. The top three SNPs from the
GWAS, rs4272382 (p=6.14610
27), rs3775182 (9.67610
27) and
rs2290344 (3.65610
26), were in genes encoding claudin 23,
MAPK10 and PIGB. For the 68 top SNPs associated with AraC
IC50 in 59 unique genes, 28 SNPs were in 39-flanking regions, 17
in 59-flanking regions and 23 in introns. None were in coding
regions. The top three SNPs for AraC were rs2604376
(p=1.84610
26), rs9512755 (p=2.54610
26) and rs2595500
(p=2.63610
26) in the TUSC3, LNX2 and ZNF215 genes. When
we compared gemcitabine and AraC, among the top SNPs that
were associated with drug IC50 values (p,0.001), only 49 were
common to both drugs (Table S3 and Figure 2).
SNP and Gene Expression Association
Among the above associated 492 associated with gemcitabine
IC50, we observed that 100 unique SNPs, located within or near
78 genes on the basis of the Illumina annotation were associated
with variation in the expression of 296 probesets (220 unique
genes) with a cutoff of p-values ,10
26. Among the 553 SNPs
associated with AraC IC50, 140 unique SNPs within or near 123
genes were associated with variation in expression of 843 (563
unique genes) expression probesets (Tables S4 and S5). Only 12
out of the 100 SNPs or 32 out of the 140 SNPs were in cis-
Figure 1. Genome-wide SNP association with drug IC50. (A). Genome-wide SNP-gemcitabine IC50 association data. (B). Genome-wide SNP-AraC
IC50 association data. Genome-wide SNPs were obtained for all 171 cell lines using Illumina 550K Beadchips. Genome-wide SNP association analysis
was then performed with gemcitabine IC50 as the drug-response phenotype (n=171). The y-axis is the 2log10 (p-value) for the SNP. SNPs are plotted
on the x-axis on the basis of their chromosomal locations. The ‘‘cut-off’’ p-value of 0.001 is highlighted with a red line.
doi:10.1371/journal.pone.0007765.g001
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as 5 Mb on either side of the gene, while the rest of the SNPs were
localized in trans-regulatory regions, consistent with previous
findings [5,26–28].
Gene Expression and IC50 Association
Among the 296 expression probesets associated with the 100
unique SNPs for gemcitabine, we determined that 35 expression
probesets were also associated with gemcitabine IC50 values
(p,0.001). These 35 probesets represented 29 genes. By
performing the same analysis for AraC, we identified 60
expression probesets that represented 54 genes which were
associated with AraC IC50 values (p,0.001). Figure 3 showed
our integrated analysis strategy, a strategy that included SNP,
gemcitabine and gene expression data. This analysis resulted in the
identification of 19 SNPs close to or within 16 genes that were
associated with gemcitabine IC50 values through an influence on
the expression of 29 genes represented by 35 expression probesets
(Table 1). The same type of analysis resulted in the identification
of 30 SNPs close to or within 30 genes that were associated with
AraC IC50 values through an influence on the expression of 54
genes represented by 60 expression probesets (Table 2). Among
the top candidate SNPs, rs3797418 (A/C), a SNP located in an
intron of IQGAP2, was significantly associated with the expression
of multiple genes and IC50 values for both drug. Therefore, this
SNP and gene were selected for further functional verification. In
addition, a second SNP, rs6082527 (A/G), located in the 59-FR of
TGM3, which was only associated with gemcitabine IC50 values,
was also selected for further functional study because of its
significant association with the expression of multiple genes, and
these genes were also significantly associated with gemcitabine
cytotoxicity, with p values ranging from 10
24 to 10
28 (Tables 1
and 2). Although the SNP in TGM3 was not significantly
associated with AraC IC50 values, given the similarity between
these two drugs, we also performed functional studies for TGM3
and its downstream gene GPM6A with AraC. Specifically,
rs3797418 was associated with the expression of 10 individual
genes for gemcitabine and 7 for AraC. rs6082527 was associated
with 6 probesets that targeted 5 individual genes.
Cytidine Analogue Pathway Gene Analysis
Gemcitabine and AraC share the same metabolism pathway
that activates these drugs in cells. There is a total of 19 genes
within this pathway (Table S6). Many previous pharmacogenetic
studies have been focused on genetic variation in genes within this
pathway, and there is evidence showing that variation in the
expression of genes within this pathway can influence response to
cytidine analogues [7,29,30]. Therefore, we took the advantage of
the genome-wide SNP data and selected all SNPs within pathway
genes that were present on the Illumina 550K chip to perform an
analysis among SNP, expression and gemcitabine and AraC IC50
values for these pathway genes. A total of 749 SNPs for cytidine
analogue pathway genes were present on the Illumina 550K chip.
Association of gemcitabine IC50 with SNPs in pathway genes
identified 38 SNPs within or close to 8 genes with p-values ,0.05,
while 23 SNPs close to 9 genes were significantly associated with
AraC IC50 values with p-values ,0.05 (Tables 3 and 4). To
Figure 2. Top candidate SNPs that overlapped between gemcitabine and AraC. 49 SNPs were common (p,0.001) among 442 unique SNPs
associated with gemcitabine and 504 associated with AraC.
doi:10.1371/journal.pone.0007765.g002
Figure 3. Strategy applied in these studies. A genome-wide SNP
association study was performed with a drug-related phenotype,
gemcitabine or AraC cytotoxicity (IC50). SNPs associated with cytotox-
icity (p,10
23) were used to perform an association study with 54,000
expression probesets to identify SNPs that were associated with both
gene expression (p,10
26) and with gemcitabine or AraC IC50. Finally,
an association study was performed with gene expression and
gemcitabine or AraC IC50 to identify SNPs that might be associated
with drug IC50 values through an influence on gene expression.
doi:10.1371/journal.pone.0007765.g003
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gene expression, we associated all of these SNPs with expression
for all genes within the pathway. That analysis identified 24 cis-
acting SNPs that regulate the expression of pathway genes with p-
values ,0.0001 (Table 5). The top three SNPs (p=7.54610
233,
1.54610
232 and 2.69610
210, respectively) were all mapped to the
NT5C3L1 gene, a nucleotidase family member (Table 5).
Functional Characterization of Candidate Genes
Our association studies were performed with human lympho-
blastoid cell lines but the gene regulation is tissue specific [31].
Therefore, to investigate the impact of the SNPs that we had
identified on gene expression and on gemcitabine and AraC
cytotoxicity and to functionally validate our association results, we
also studied tumor cell lines, in this case, two pancreatic cancer cell
lines, to validate our association results. We performed siRNA
knock down for three SNP-associated genes, including VAV3,
MGMT that are associated with the SNP in IQGAP2 and GPM6A
which is associated with the SNP in TGM3, to determine whether
genes that had expression associated with the two SNPs might
influencedrug IC50. We selected VAV3 and GPM6A because eachof
these genes had two probesets associated with rs3797418 and
rs6082527, respectively. VAV3 was also highly associated with
gemcitabine and AraC IC50 while GPM6A gene expression was
associated with gemcitabine IC50 (Figure 4A and 4B). As with
TGM3, we also performed knock down of GPM6A for AraC.
However, the association was most significant in the CA group,
which could be due to differences in allele frequencies among the
three ethnic groups studied. Expression of the third gene, MGMT,
was also associated with both SNPs (rs3797418 with p=1.22610
27
and rs6082527 with p=8.06610
28) and with gemcitabine and
AraC IC50 values (p=5.49610
28 and 1.85610
24, respectively).
We also included IQGAP2 and TGM3 in the siRNA knock down
studies to determine whether the genes harboring these two SNPs
might themselves have functional effects on gemcitabine or AraC
cytotoxicity. Finally, we included a positive control siRNA, FKBP5,
a gene that we had previously shown to be important for
gemcitabine response [25].
Specific and negative control siRNAs were transiently trans-
fected into human SU86 or Hup-T3 pancreatic cancer cell lines,
cell lines selected on the basis of endogenous expression level of
genes of interest, followed by gemcitabine or AraC cytotoxicity
assays. We selected pancreatic cancer cell lines because gemcita-
bine is the standard of care for the therapy of pancreatic cancer.
Down regulation of VAV3 in SU86 cells significantly desensitized
the cells to gemcitabine and AraC (Figure 5A), consistent with the
result of the association study (gemcitabine p=9.14E-10 and AraC
p=1.24E-11). Down regulation of GPM6A in HupT3 cell line
also resulted in desensitization to gemcitabine (p=1.35E-07), an
observation consistent with our association study results for
GPM6A gene expression and gemcitabine IC50 (Figure 5B).
Interestingly, although GPM6A expression was not significantly
associated with AraC response, the knock down experiments
showed a similar effect for AraC (p=3.66E-12) (Figure 5B). We
also performed similar experiments of knock down of these two
genes using selected lymphoblastoid cell lines and it showed similar
results as in the tumor cell lines (Figure 5A right panel, AraC
p=0.0074, gemcitabine p=0.0085; Figure 5B right panel, AraC
p=0.001, gemcitabine p=0.002). However, down-regulation of
MGMT did not alter either gemcitabine or AraC cytotoxicity.
Furthermore, knock down of IQGAP2 and TGM3 themselves, did
not have significant effect on gemcitabine or AraC cytotoxicity, an
observation indicating that the genes harboring these two SNPs
might not have a direct effect on cytotoxicity for the two drugs,
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PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7765and that rs3797418 and rs6082527 might just be markers for
gemcitabine and/or AraC cytotoxicity.
Characterization of SNPs in IQGAP2 and TGM3
In order to further characterize the two SNPs (rs3797418 and
rs6082527) in IQGAP2 and TGM3,w ea l s op e r f o r m e dg e n o t y p e -
phenotype correlation studies with the expression of these two genes,
i.e., we determined the possible cis-association of the SNPs with
IQGAP2 and TGM3 expression. However, neither SNP was
associated with the expression of either IQGAP2 or TGM3,
indirectly supporting the results of the IQGAP2 and TGM3 knock
down experiments. We then determined LD patterns for 500 kb
regions around each of the two SNPs using the HapMap data for
each ethnic group. As shown in Figure 6. LD patterns surrounding
the two SNPs differed among the three ethnic groups. No SNPs
within the 500 kb region around rs3797418 were in high LD with
rs3797418. One SNP, rs6047696 in an intergenic region, was in
moderate LD with rs6082527 in the CEPH population (r
2=0.682,
D9=0.826). In addition, rs12479538, located in an intron of STK35,
a serine/threonine kinase 35, was in complete linkage disequilibrium
Table 3. Top 38 significant SNPs within or close to 8 pathway genes associated with gemcitabine IC50 values (p,0.05).
SNP r-value p-value q-value N MAF Chr Position
Genome
Build
Gene
Symbol Gene Location
Location
Relative
to Gene
rs2037067 0.269 0.001 0.82119 170 0.471 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2237660
rs3775289 0.227 0.005 0.82119 170 0.203 4 72081538 36.1 DCK NM_000788.1 Intron 21110
rs4308342 0.227 0.005 0.82119 170 0.203 4 72103069 36.1 DCK NM_000788.1 Intron 23879
rs956727 20.218 0.007 0.82119 171 0.117 9 86036753 36.1 SLC28A3 NM_022127.1 flanking_3UTR 246159
rs515583 0.211 0.009 0.82119 171 0.19 6 85933010 36.1 NT5E NM_002526.1 flanking_5UTR 2283518
rs13144500 20.205 0.011 0.82119 171 0.123 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2335310
rs12500335 20.202 0.013 0.82119 170 0.091 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2103463
rs3966882 0.202 0.013 0.82119 168 0.318 6 85938190 36.1 NT5E NM_002526.1 flanking_5UTR 2278338
rs10006225 0.200 0.013 0.82119 171 0.064 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2102248
rs1932660 0.200 0.013 0.82119 171 0.234 9 86017079 36.1 SLC28A3 NM_022127.1 flanking_3UTR 265833
rs4877822 0.200 0.013 0.82119 171 0.234 9 86021002 36.1 SLC28A3 NM_022127.1 flanking_3UTR 261910
rs7874528 20.198 0.014 0.82119 171 0.17 9 86020319 36.1 SLC28A3 NM_022127.1 flanking_3UTR 262593
rs9472236 0.196 0.015 0.82119 171 0.225 6 44314728 36.1 SLC29A1 NM_004955.1 flanking_3UTR 24872
rs1570933 0.196 0.015 0.82119 171 0.292 6 85937335 36.1 NT5E NM_002526.1 flanking_5UTR 2279193
rs17087049 20.194 0.017 0.82119 171 0.208 9 86104192 36.1 SLC28A3 NM_022127.1 Intron 2124
rs10780659 20.193 0.017 0.82119 171 0.146 9 86071310 36.1 SLC28A3 NM_022127.1 flanking_3UTR 211602
rs7173860 0.192 0.017 0.82119 171 0.465 15 83230545 36.1 SLC28A1 NM_004213.3 Intron 2362
rs7597224 0.189 0.019 0.85358 171 0.342 2 18829103 36.1 NT5C1B NM_001002006.1 flanking_5UTR 2194784
rs12683783 20.188 0.020 0.82119 171 0.126 9 86060628 36.1 SLC28A3 NM_022127.1 flanking_3UTR 222284
rs10122651 20.188 0.020 0.82119 171 0.468 9 86123704 36.1 SLC28A3 NM_022127.1 Intron 25515
rs9294329 20.187 0.021 0.82119 171 0.295 6 85958337 36.1 NT5E NM_002526.1 flanking_5UTR 2258191
rs10780663 20.186 0.022 0.82119 170 0.465 9 86120882 36.1 SLC28A3 NM_022127.1 Intron 22693
rs9362176 20.181 0.025 0.82119 171 0.152 6 86036174 36.1 NT5E NM_002526.1 flanking_5UTR 2180354
rs4585823 20.179 0.026 0.82119 171 0.132 9 86094005 36.1 SLC28A3 NM_022127.1 Intron 2884
rs12684950 20.178 0.027 0.82119 171 0.155 9 86066751 36.1 SLC28A3 NM_022127.1 flanking_3UTR 216161
rs556388 0.178 0.028 0.82119 171 0.447 8 1.03E+08 36.1 RRM2B NM_015713.3 flanking_3UTR 2110177
rs10955282 0.179 0.028 0.82119 170 0.488 8 1.03E+08 36.1 RRM2B NM_015713.3 flanking_3UTR 239785
rs10780656 0.178 0.028 0.82998 171 0.196 9 86031222 36.1 SLC28A3 NM_022127.1 flanking_3UTR 251690
rs1321742 20.175 0.032 0.82119 170 0.444 6 85937908 36.1 NT5E NM_002526.1 flanking_5UTR 2278620
rs501344 0.172 0.034 0.83550 171 0.327 8 1.03E+08 36.1 RRM2B NM_015713.3 flanking_3UTR 2102158
rs3743162 0.171 0.035 0.82119 171 0.129 15 83231973 36.1 SLC28A1 NM_201651.1 Intron 27
rs11885014 20.173 0.035 0.82119 167 0.272 2 18810796 36.1 NT5C1B NM_001002006.1 flanking_5UTR 2176477
rs9990999 0.170 0.037 0.83550 169 0.352 4 1.84E+08 36.1 DCTD NM_001921.2 Intron 28215
rs944664 20.166 0.041 0.82119 171 0.444 6 85945694 36.1 NT5E NM_002526.1 flanking_5UTR 2270834
rs4877824 0.165 0.042 0.82119 171 0.38 9 86045679 36.1 SLC28A3 NM_022127.1 flanking_3UTR 237233
rs2251530 20.163 0.044 0.82119 171 0.386 9 86002760 36.1 SLC28A3 NM_022127.1 flanking_3UTR 280152
rs4507403 0.164 0.046 0.82119 166 0.41 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2251819
rs6850978 0.159 0.050 0.82119 171 0.424 4 1.84E+08 36.1 DCTD NM_001012732.1 flanking_3UTR 2238854
doi:10.1371/journal.pone.0007765.t003
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PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7765with rs6082527 in the Han Chinese population (r
2=1,D9=1).The
p-value for the association between the rs6082527 SNP and
gemcitabine IC50 was 0.006, which was not significant after
correction for multiple comparisons. Unfortunately, the rs12479538
SNP was not on the 550K SNP array. Obviously, the association of
the two SNPs in IQGAP2 and TGM3 with gemcitabine or AraC
response and with the expression of other genes might result from the
effects of either known or unknown polymorphisms in tight linkage
disequilibrium with these two SNPs.
Since these two SNPs, rs3797418 (A/C) and rs6082527 (A/G),
were located in the intron of IQGAP2 and the 59-FR of TGM3,
respectively, we determined the relationship among genes
associated with these two SNPs. Ingenuity Pathway analysis was
performed by mapping the 10 and 8 unique genes that were
significantly associated with rs3797418 in IQGAP2 for gemcitabine
and AraC, respectively. Results of the Ingenuity Pathway Analysis
showed a network that connected all of the 10 genes centered on
ERK and TNF for gemcitabine and all of the 8 genes centered on
TNF, ERK, TP53 for AraC (Figure S1). However, since only 5
genes were identified to be associated with rs6082527 through our
analysis, no network was identified when we analyzed genes that
were associated with this SNP.
Discussion
Variation in response to chemotherapeutic agents is a common
phenomenon in the clinic. Many factors can contribute to this
variation. However, genetic variation is one of the major factors
that play an important role in determining response to drugs.
Therefore, it is important to identify SNPs that might be used as
predictive markers for drug response. In a previous study, we
identified candidate genes for which variation in expression levels
were associated with variation in response to gemcitabine and
AraC using a lymphoblastoid cell line model system [25]. In the
current set of experiments, we expanded our study to include
genome-wide SNPs to test the hypothesis that SNPs across the
genome might contribute significantly to variation in response to
two cytidine analogues, gemcitabine and AraC. Lymphoblastoid
cell lines with genome-wide SNP and expression data have been
used successfully to identify pharmacogenomic candidates associ-
ated with response to other chemotherapeutic agents [26,32]. The
advantage of using this cell-based model system is that we have
obtained different types of high throughput genomic and
transcriptomic data, which makes it possible to test the hypothesis
that genetic variation might contribute to variation in drug
response, in this case, two cytidine analogues [18,19,33,34]. Many
previous pharmacogenetic studies for these two drugs were focused
on the gemcitabine bioactivation and metabolism pathway
[35,36]. For example, SNPs identified in genes encoding
ribonucleotide reductase (RRM1) and cytidine deaminase (CDA)
were found to be associated with gemcitabine chemosensitivity in
the NCI60 cell lines or with active gemcitabine plasma metabolites
levels [37–39]. Those findings provided the initial evidence that
genetic variation might contribute to the variation in cytidine
analogue response.
Table 4. Top 23 significant SNPs within or close to 9 pathway genes associated with AraC IC50 values (p,0.05).
SNP r-value p-value q-value N MAF Chr Position
Genome
Build
Gene
Symbol Gene Location
Location
Relative
To Gene
rs9472236 0.240 0.003 0.99971 173 0.225 6 44314728 36.1 SLC29A1 NM_004955.1 flanking_3UTR 24872
rs2037067 0.222 0.006 0.99971 172 0.471 4 183810578 36.1 DCTD NM_001012732.1 flanking_3UTR 2237660
rs11999726 20.219 0.006 0.99971 173 0.073 9 86104976 36.1 SLC28A3 NM_022127.1 intron 2516
rs7830150 20.213 0.008 0.99971 173 0.187 8 103162269 36.1 RRM2B NM_015713.3 flanking_3UTR 2123638
rs1614627 20.196 0.015 0.99971 173 0.17 1 20819343 36.1 CDA NM_001785.1 flanking_3UTR 21360
rs2224211 0.192 0.017 0.99971 173 0.196 6 85619788 36.1 NT5E NM_002526.1 flanking_5UTR 2596740
rs7874528 20.183 0.023 0.99971 173 0.17 9 86020319 36.1 SLC28A3 NM_022127.1 flanking_3UTR 262593
rs17414857 20.182 0.023 0.99971 173 0.094 8 103139477 36.1 RRM2B NM_015713.3 flanking_3UTR 2146430
rs4877839 20.182 0.024 0.99971 173 0.12 9 86118829 36.1 SLC28A3 NM_022127.1 intron 2640
rs17343066 0.181 0.024 0.99971 173 0.36 9 86135893 36.1 SLC28A3 NM_022127.1 intron 29416
rs12526113 20.181 0.024 0.99971 173 0.33 6 85612351 36.1 NT5E NM_002526.1 flanking_5UTR 2604177
rs2324753 20.181 0.024 0.99971 173 0.33 6 85615181 36.1 NT5E NM_002526.1 flanking_5UTR 2601347
rs12554292 20.180 0.025 0.99971 173 0.135 9 86256385 36.1 SLC28A3 NM_022127.1 flanking_5UTR 283152
rs1570311 20.175 0.029 0.99971 173 0.161 6 86211870 36.1 NT5E NM_002526.1 flanking_5UTR 24658
rs4487548 20.175 0.029 0.99971 173 0.161 6 86199130 36.1 NT5E NM_002526.1 flanking_5UTR 217398
rs9344525 20.175 0.029 0.99971 173 0.161 6 86208157 36.1 NT5E NM_002526.1 flanking_5UTR 28371
rs6850978 0.171 0.034 0.99971 173 0.424 4 183809384 36.1 DCTD NM_001012732.1 flanking_3UTR 2238854
rs9450270 20.170 0.034 0.99971 173 0.187 6 86171485 36.1 NT5E NM_002526.1 flanking_5UTR 245043
rs3743162 0.170 0.034 0.99971 173 0.129 15 83231973 36.1 SLC28A1 NM_201651.1 intron 27
rs1265138 0.165 0.042 0.99971 171 0.148 8 103269212 36.1 RRM2B NM_015713.3 flanking_3UTR 216695
rs1569040 0.163 0.043 0.99971 172 0.147 17 17246812 36.1 NT5M NM_020201.3 flanking_3UTR 255110
rs12500335 20.162 0.044 0.99971 172 0.091 4 183944775 36.1 DCTD NM_001012732.1 flanking_3UTR 2103463
rs11598702 20.163 0.045 0.99971 171 0.246 10 104887975 36.1 NT5C2 NM_012229.2 intron 21178
doi:10.1371/journal.pone.0007765.t004
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PLoS ONE | www.plosone.org 11 November 2009 | Volume 4 | Issue 11 | e7765In the present study, we performed a genome-wide association
study with 171 lymphoblastoid cell lines for which we obtained
genome-wide SNPs by use of Illumina 550K SNP chips, as well as,
expression array data obtained with Affymetrix U133 Plus 2.0
GeneChips. Those data made it possible for us to take a
comprehensive approach in which we combined genotype,
expression and cytotoxicity data for the two cytidine analogues
(Figure 3) to identify SNPs that might contribute to drug sensitivity
throughtheirimpactontheregulationofgeneexpression(Tables1
and 2). However, there were only 49 SNPs among the top
significant SNPs for gemcitabine and AraC that were common for
both drugs, indicating even though the two drugs share common
mechanisms and the same metabolic pathway, there are differences
between these two drugs. This stepwise analysis helped us to narrow
our focus to two SNPs associated with both expression and drug
cytotoxicity. Those two SNPs, rs3797418 and rs6082527, were
located, respectively, in an intron of IQGAP2 and the 59-FR of
TGM3. To further understand the biology responsible for the
association of rs3797418 and rs6082527 with gene expression and
drug cytotoxicity, we performed knock down of selected genes with
expression that was associated with these two SNPs. Knock down of
VAV3 and GPM6A in pancreatic cancer cell lines desensitized the
cells to gemcitabine and AraC (Figure 5A and 5B). VAV3 is a
member of the VAV family that has guanine nucleotide exchange
activity toward small GTP-binding proteins. VAV3 is a known
proto-oncogene that can be involved in tumorgenesis [40–42]. As
shown in our network analysis (Figure S1), VAV3 can be involved
in multiple signaling pathways. Although the mechanism respon-
sible for VAV3 involvement in gemcitabine and AraC response is
unclear, given the multiple roles of VAV3 in cancer development, it
was not surprising that this gene might contribute to variation in
response to chemotherapeutic agents. GPM6A, also known as M6a,
is a transmembrane glycoprotein that belongs to the myelin
protolipid protein (PLP) family. This gene is expressed mainly in
nervoussystem, and recentstudies have suggested theimportanceof
GPM6A in processes involved in neural development such as
neurite extension, survival and differentiation [43–45]. GPM6A
also interacts with a number of G protein coupled receptors and
downstream signaling pathways [46]. One recent report suggested
thatGPM6Amightfunctionasa chaperone incancercellsaspart of
global profiling of the cell surface proteome for cancer cells [47].
Although there is limited information with regard to the
involvement of this gene in tumorgenesis and drug resistance, our
results suggest a possible role for GPM6A in response to cytidine
analogue antineoplastic agents.
Although the two SNPs in IQGAP2 and TGM3 that we studied
were associated with multiple downstream genes with expression
that was also associated with gemcitabine or AraC cytotoxicity, we
did not identify an association between these two SNPs and either
IQGAP2 and TGM3 gene expression, nor did we observe an
influence of IQGAP2 and TGM3 on gemcitabine or AraC
cytotoxicity after knock down of these two genes.
Table 5. 24 candidate SNPs with cis-regulation of pathway genes (p,0.0001).
SNP Probeset
r-value
(SNP vs
Exp)
p-value
(SNP vs
Exp) SNP MAF Chr Position
Genome
Build
Gene
Symbol Gene Location
Location
Relative
to Gene
rs1319763 225044_at 0.6435 7.54E-33 rs1319763 0.22 17 37245316 36.1 NT5C3L NM_052935.2 intron 2266
rs1046403 225044_at 0.6420 1.54E-32 rs1046403 0.219 17 37237346 36.1 NT5C3L NM_052935.2 coding [142/58]
rs4796712 225044_at 0.3728 2.69E-10 rs4796712 0.099 17 37240656 36.1 NT5C3L NM_052935.2 coding [77/12]
rs9344525 227486_at 20.3034 3.91E-07 rs9344525 0.167 6 86208157 36.1 NT5E NM_002526.1 flanking_5UTR 28371
rs1570311 227486_at 20.3034 3.91E-07 rs1570311 0.167 6 86211870 36.1 NT5E NM_002526.1 flanking_5UTR 24658
rs4487548 227486_at 20.3034 3.91E-07 rs4487548 0.167 6 86199130 36.1 NT5E NM_002526.1 flanking_5UTR 217398
rs9344525 203939_at 20.2821 2.59E-06 rs9344525 0.167 6 86208157 36.1 NT5E NM_002526.1 flanking_5UTR 28371
rs1570311 203939_at 20.2821 2.59E-06 rs1570311 0.167 6 86211870 36.1 NT5E NM_002526.1 flanking_5UTR 24658
rs4487548 203939_at 20.2821 2.59E-06 rs4487548 0.167 6 86199130 36.1 NT5E NM_002526.1 flanking_5UTR 217398
rs7277 201572_x_at 20.2768 4.20E-06 rs7277 0.341 4 184048507 36.1 DCTD NM_001012732.1 3UTR [269/1038]
rs9344525 1553995_a_at 20.2709 6.56E-06 rs9344525 0.167 6 86208157 36.1 NT5E NM_002526.1 flanking_5UTR 28371
rs1570311 1553995_a_at 20.2709 6.56E-06 rs1570311 0.167 6 86211870 36.1 NT5E NM_002526.1 flanking_5UTR 24658
rs4487548 1553995_a_at 20.2709 6.56E-06 rs4487548 0.167 6 86199130 36.1 NT5E NM_002526.1 flanking_5UTR 217398
rs4910907 201477_s_at 20.2705 6.81E-06 rs4910907 0.167 11 4125427 36.1 RRM1 NM_001033.2 flanking_3UTR 28745
rs9907244 225044_at 20.2650 1.05E-05 rs9907244 0.455 17 37234426 36.1 NT5C3L NM_052935.2 flanking_3UTR 2558
rs9344525 1553994_at 20.2621 1.33E-05 rs9344525 0.167 6 86208157 36.1 NT5E NM_002526.1 flanking_5UTR 28371
rs1570311 1553994_at 20.2621 1.33E-05 rs1570311 0.167 6 86211870 36.1 NT5E NM_002526.1 flanking_5UTR 24658
rs4487548 1553994_at 20.2621 1.33E-05 rs4487548 0.167 6 86199130 36.1 NT5E NM_002526.1 flanking_5UTR 217398
rs2250159 203302_at 20.2613 1.46E-05 rs2250159 0.369 9 85966866 36.1 SLC28A3 NM_022127.1 flanking_3UTR 2116046
rs1474500 201477_s_at 20.2561 2.11E-05 rs1474500 0.166 11 4080688 36.1 RRM1 NM_001033.2 intron 2801
rs12990630 1553540_a_at 20.2518 2.94E-05 rs12990630 0.082 2 18973412 36.1 NT5C1B NM_001002006.1 flanking_5UTR 2339093
rs4910896 201477_s_at 20.2492 3.58E-05 rs4910896 0.172 11 4118132 36.1 RRM1 NM_001033.2 flanking_3UTR 21450
rs16845804 236703_at 0.2410 6.54E-05 rs16845804 0.221 4 72208285 36.1 DCK NM_000788.1 flanking_3UTR 292808
rs17271644 201572_x_at 20.2376 8.30E-05 rs17271644 0.495 4 184046266 36.1 DCTD NM_001012732.1 flanking_3UTR 21972
doi:10.1371/journal.pone.0007765.t005
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length. Figure 6 shows the haplotype structure within ,300 kb
surrounding the rs3797418 and rs6082527 SNPs. Linkage analysis
was also performed with HapMap data sets in different ethnic
groups. However, one of the SNPs linked to rs6082527 was not
associated with gemcitabine IC50, and the other was not present
on the 550K SNP array. Therefore, the effect of the two SNPs in
IQGAP2 and TGM3 on drug response and other gene expression
might result from the effects of either known or unknown
polymorphisms linked to those two SNPs.
In summary, we have used a data-rich cell-based model system
to perform association studies of gemcitabine and AraC cytotox-
icity with genome-wide SNP and expression array data. Use of this
approach enabled us to identify SNPs that might be markers for
cytidine analogue sensitivity and genes that might play an
important role in variation in response to these drugs. There are
also limitations associated with the use of these cell lines, as
described by Choy et. al [48]. The potential confounding factors
besides genetic effect could include cell growth rate, EBV
transformation and ATP condition. However, that same paper
stated that ‘‘RNA levels are predominantly correlated to inter-
individual differences in EC50. Much less of the correlation
between RNA and EC50s reflects intra-individual variation’’.
That conclusion supports the hypothesis that inter-individual
variation in RNA levels due to genetic variation may contribute to
variation in drug response phenotype. One limitation of the use of
these cell lines is the possibility that EBV transformation might
influence drug sensitivity and/or expression profiles, so we might
miss some genes of importance for the drug response phenotype,
either because they are not expressed in these cell lines or, after
transformation, are down-regulated. There is also evidence that
gemcitabine and doxorubicin can induce the lytic form of EBV
transformed cells [49,50]. However, we and other groups have
demonstrated success with the use of this type of cell line in
previous pharmacogenomic studies [25,26,51], and functional
characterization of the genes identified during the present study
supports the feasibility of this approach. The results of the present
study enhance our understanding of the role of genetic variation in
variation in gemcitabine and AraC sensitivity and resistance and
may help to identify mechanisms involved in the actions of these
drugs. In addition, these SNPs and genes can now potentially be
tested in the clinical setting and, if confirmed, they could
significantly enhance our ability to individualize treatment with
these two drugs.
Figure 4. Association among SNPs in IQGAP2 and TGM3 with expression and gemcitabine or AraC cytotoxicity. (A) SNP rs3797418 (A/C)
association with VAV3 expression, gemcitabine IC50 values and VAV3 expression association with gemcitabine IC50 in individual ethnic groups and all
of the cell lines. (B) SNP rs6082527 (A/G) association with GPM6A gene expression, gemcitabine IC50 values and GPM6A gene expression association
with gemcitabine IC50 values. (C). SNP rs3797418 (A/C) association with VAV3 expression, AraC IC50 values and VAV3 expression association with AraC
IC50 in individual ethnic groups and all of the cell lines. Each dot represents one sample. Genotypes for each SNP are plotted against gene expression
levels (upper panels) as well as gemcitabine or AraC IC50 values (middle panels). In the lower panel, correlations were determined between gene
expression levels and gemcitabine or AraC IC50 values.
doi:10.1371/journal.pone.0007765.g004
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Cell Line
174 lymphoblastoid cell lines from 60 Caucasian-American
(CA), 54 African-American (AA) and 60 Han Chinese-American
(HCA) (sample sets HD100CAU, HD100AA, and HD100CHI)
subjects were purchased from the Coriell Cell Repository
(Camden, NJ). All of these cell lines had been obtained and
anonymized by the National Institute of General Medical Sciences
prior to deposit, and all subjects had provided written consent for
the use of their DNA and cells for experimental purposes. Human
SU86 and Hup-T3 pancreatic cancer cell lines were gifts from Dr.
Daniel D. Billadeau, Mayo Clinic.
siRNA
The siRNA duplexes used in the knock down studies were
purchased from the QIAGEN Inc. (Valencia, CA).
Drugs and Cell Proliferation Assays
Gemcitabine was provided by Eli Lilly (Indianapolis, IN). AraC
was purchased from Sigma-Aldrich (St. Louis, MO). Cytotoxicity
assays with the lymphoblastoid cell and tumor cell lines were
performed with the CellTiter 96H AQueous Non-Radioactive Cell
Proliferation Assay (Promega Corporation, Madison, WI) as
previously described [25]. Estimation of the IC50 phenotype
(effective dose that kills 50% of the cells) was calculated using a
four parameter logistic model. Of the 174 cell lines, cytotoxicity
curves for two cell lines were removed from further analysis due to
possible experimental error.
Gene Expression
Expression array data were obtained for all 174 lymphoblastoid
cell lines as previously described [25]. Specifically, biotin-labeled
cRNA, produced by in vitro transcription, was hybridized to
Affymetrix Human Genome U133 Plus 2.0 GeneChips. Each of
these GeneChip contains 54,613 probesets. Normalization of the
expression array data was performed using GCRMA [52,53].
Genome-Wide SNP Analysis
Illumina HumanHap 550K BeadChips were used to obtain
genome-wide SNP data for all 174 cell lines. Specifically, each
DNA sample was genotyped using the Illumina version 3
BeadChip, which assays 561,278 single nucleotide polymorphisms
(SNPs). All genotyping was conducted at the Genotype Shared
Resource (GSR) at the Mayo Clinic, Rochester, MN. SNPs with
call rates ,0.95 were excluded, as were DNA samples with call
rates ,0.95. The call rate for rs3797418 and rs6082527 SNPs
were 100% for all cell lines. One African American sample was
removed due to a call rate ,0.95, resulting in 173 cell lines with
genotypic data and 171 cell lines with both genotypic data and
phenotypic data (gemcitabine IC50 values)
Transient Transfection and RNA Interference
Human SU86 and HupT3 pancreatic cancer cell lines were
used to perform the siRNA studies. The Hiperfect transfection
reagent (QIAGEN) was used for siRNA reverse transfection.
Specifically, cells were seeded into 96-well plates and were mixed
with siRNA-complex, consisting of 5 nM of specific or negative
control siRNA (QIAGEN), and the Hiperfect transfection reagent.
Figure 5. Functional characterization of candidate genes with siRNA knock down of VAV3 (A) and GPM6A (B). Knock down of VAV3
and GPM6A expression in human SU86 and Hup-T3 pancreatic cancer cell lines as well as lymphoblastoid cell lines showed increased resistance to
gemcitabine and AraC after siRNA knock down as determined by MTS assays. Error bars represent SEM values for 3 independent experiments.
Quantitative RT-PCR was performed to assess VAV3 and GPM6A gene expression levels after knock down with specific siRNAs. Results are expressed
as % of control. Error bars represent SEM values for 3 independent experiments. * =p,0.05.
doi:10.1371/journal.pone.0007765.g005
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PLoS ONE | www.plosone.org 14 November 2009 | Volume 4 | Issue 11 | e7765The lymphoblastoid cell lines were transfected with control siRNA
and specific siRNA for GPM6A and VAV3 using the electropo-
ration (NucleofectorH Lonza Walkersville Inc., Walkersville, MD).
Specifically, 1.25610
6 cells suspended in Cell Line Nucleofector
Solution V (Lonza Walkersville Inc.) were mixed with 2 mM
control or specific siRNA before the electroporation.
Quantitative Real-Time Reverse Transcription-PCR
Total RNA was isolated from cultured cells with the Qiagen
RNeasy kit (QIAGEN Inc. Valencia, CA), followed by QRT-PCR
performed with the 1-step, Brilliant SYBR Green QRT-PCR
master mix kit (Stratagene, La Jolla, CA). Specifically, primers
purchased from Qiagen were used to perform QRT-PCR using
the Stratagene Mx3005P
TM Real-Time PCR detection system
(Stratagene). All experiments were performed in triplicate with b-
actin as an internal control. Reverse transcribed Universal Human
reference RNA (Stratagene) was used to generate a standard
curve. Control reactions lacked RNA template.
Statistical Methods
Quality control for the Illumina genotypes was performed before
performing the association study. SNPs that deviated from HWE
Figure6.Linkagedisequilibriumwithin,300 Kbsurroundingthers3797418andrs6082527SNPs.RedindicatescombinationswhereD9=1
and linkage of disequilibrium (LOD) $2; light red, combinations where D9,1 and LOD $2; red squares, combinations where D9=1andLOD,2; white
squares, combinations with D9,1 and LOD ,2. SNPs are arranged in order from 59 to 39 in each gene, as shown in the gene structure above each plot.
doi:10.1371/journal.pone.0007765.g006
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PLoS ONE | www.plosone.org 15 November 2009 | Volume 4 | Issue 11 | e7765(minimum exact test for HWE [54,55] and stratified test for HWE
[56] p-values ,0.001), with call rates ,95% or SNPs with MAFs
,5% were removed from the analysis. Subjects with call rates ,95%
were also removed from all SNP analyses. No effects for SNPs were
seen with the Illumina platforms. The plot for the most significant
SNPs are shown in Figure S2. Next, population stratification was
assessed. Because we studied cell lines chosen to represent common
human genetic diversity, multiple races/ethnic groups were repre-
sented in the lymphoblastoid cell lines. Therefore, we used the
method developed by Price et al. [57] to adjust for population
stratification. This method uses an eigen analysis to detect and adjust
for population stratification. Within each race, eigen analysis was
completed, with the top five eigenvectors saved. Using the five
eigenvectors within each race, individual genotypes were adjusted
using the model Gij~ajzckjzeij, with Gij representing the
genotype for the i
th cell line in racial group j (j=1 ,2 ,3 ) ,aj the race
effect for race j,a n dckj the k
th eigenvector, k=1 ,5 ,e f f e c tf o rr a c ej.
Similarly,the log transformed IC50 values, were also adjusted for race
using the five eigenvectors, in addition to gender. Pearson correlation
coefficients were then computed using the adjusted genotypes and
IC50 variables. False Discovery q-values [58,59] were also computed
for each test. Similar sets of analyses were also performed for the
association of IC50 with mRNA expression and SNPs with mRNA
expression. Pairwise LD was estimated using r-squared statistics and
were displayed graphically using the Haploview software [60].
Integrative Genomic Analysis
To integrate genotype, expression and drug cytotoxicity data, we
used an approach similar to ‘‘genomic convergence’’ [61–63], as
depicted graphically in Figure 2.Weused a lessstringent cutoffforp-
values used to identify the initial set of SNPs that were associated with
IC50 to avoid missing possible candidates with biological significance.
First, we identify SNPs associated with IC50 (p-values ,0.001). One of
the functional mechanisms by which SNPs might influence
cytotoxicity is by regulating transcription in either a cis (SNP within
or near the gene) or trans- (SNP not within or near the gene) manner.
Therefore, we determined the expression probesets that were
associated with these identified SNPs (p-values ,10
26). Next, to
determine whether the expression probesets associated with these
SNPs were also associated with IC50 values for gemcitabine and AraC,
we correlated these expression probesets with IC50 for both drugs with
ap ,0.001. A set of genes was then selected to test functionally for
their possible biological relevance with regard to drug response.
Bioinformatics Pathway Analysis
To further understand biological interactions between the
downstream genes, pathway analysis was performed on genes
that had significant associations with the two SNPs and with
phenotype. In the case of gemcitabine, SNP rs3797418 present in
the intronic region of IQGAP2 showed significant associations with
14 probesets during the SNP-expression analysis; and these same
14 probesets also had significant correlations with IC50 phenotype.
Therefore, these14 probesets that mapped to 10 unique genes
were used to perform pathway analysis. A similar analysis was
performed with AraC using the 8 genes that were significantly
associated with the SNP rs3797418 to perform the pathway
analysis. SNP rs6082527 close to TGM3 gene was associated with
6 probesets that showed significant correlations with IC50
phenotype. Therefore, pathway analysis was also performed for
the 6 probesets that mapped to 5 genes to identify major pathways
that might be involved with the downstream effects of this SNP.
Ingenuity software was used to perform the pathway analysis. This
software consists of a curated database and several analysis tools to
obtain pathways associated with a set of genes. Ingenuity calculates
p-value for the probability of finding a set of genes within a given
pathway. Fisher’s exact test is used to calculate the p-values.
Supporting Information
Table S1 Top polymorphism associated with gemcitabine
cytotoxicity (IC50 values). 492 significant SNPs were associated
with gemcitabine IC50 values with p-values ,0.001.
Found at: doi:10.1371/journal.pone.0007765.s001 (0.09 MB
XLS)
Table S2 Top candidates for association between 550K
genome-wide SNPs and AraC cytotoxicity. 553 significant SNPs
were associated with AraC IC50 values with p-values ,0.001.
Found at: doi:10.1371/journal.pone.0007765.s002 (0.10 MB
XLS)
Table S3 Top SNPs that were significantly associated with both
gemcitabine and AraC (p,0.001).
Found at: doi:10.1371/journal.pone.0007765.s003 (0.05 MB
XLS)
Table S4 Top candidates for association between 492 SNPs and
whole gene expression array data (54,000 probe sets). 100 SNPs
among 492 located within or close to 78 genes were associated
with 296 expression probe sets (220 unique genes) with p-values
,1026.
Found at: doi:10.1371/journal.pone.0007765.s004 (0.19 MB
XLS)
Table S5 Top candidates for association between 553 SNPs and
whole gene expression data (54,000 probesets). 140 SNPs among
553 SNPs located within or close to 843 probe sets (563 unique
genes) with p-values ,1026.
Found at: doi:10.1371/journal.pone.0007765.s005 (0.33 MB
XLS)
Table S6 Genes within the gemcitabine/AraC transport,
metabolism and target pathway.
Found at: doi:10.1371/journal.pone.0007765.s006 (0.02 MB
PDF)
Figure S1 Network analysis. Genes that were associated with
rs3797418, an intron SNP in IQGAP2, were used to perform
network analysis using Ingenuity Pathway Analysis. Dotted line
indicates an indirect connection and solid lines indicate a direction
interaction between genes.
Found at: doi:10.1371/journal.pone.0007765.s007 (0.32 MB
PDF)
Figure S2 Illumina intensity plot for top candidate SNPs.
Found at: doi:10.1371/journal.pone.0007765.s008 (0.13 MB
PDF)
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